AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Faruqi & Faruqi Investigates Rocket Pharmaceuticals Securities Litigation
ByAinvest
Saturday, Aug 9, 2025 8:05 am ET1min read
Faruqi & Faruqi LLP is investigating potential claims against Rocket Pharmaceuticals due to alleged securities violations. Investors who purchased securities between February 27, 2025 and May 26, 2025 are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330. The deadline to seek the role of lead plaintiff is August 11, 2025.
Investors who purchased or acquired Rocket Pharmaceuticals, Inc. (RCKT) securities between February 27, 2025, and May 26, 2025, are encouraged to contact the law offices of Faruqi & Faruqi, LLP, to discuss their legal options. The firm has set August 11, 2025, as the deadline for investors to seek the role of lead plaintiff in a federal securities class action lawsuit against the company [2].The lawsuit alleges that Rocket Pharmaceuticals made materially false and misleading statements and failed to disclose critical information about its clinical trial, RP-A501, for the treatment of Danon disease. Specifically, the complaint claims that Rocket knew of Serious Adverse Events (SAEs), including the death of participants, but did not disclose these risks to investors [2]. Additionally, the company amended the trial's protocol to introduce a novel immunomodulatory agent without informing shareholders [2].
On May 27, 2025, Rocket announced that the FDA had placed a clinical hold on the RP-A501 Phase 2 pivotal study following an SAE, which led to a significant drop in the company's stock price. Rocket's stock price fell from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, a decline of about 37% [2].
Investors who believe they have been affected by these alleged securities violations are urged to contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights [2].
References:
[1] https://www.morningstar.com/news/business-wire/20250808067854/deadline-soon-rocket-pharmaceuticals-inc-rckt-investors-who-lost-money-urged-to-contact-the-law-offices-of-frank-r-cruz-about-securities-fraud-lawsuit
[2] https://www.prnewswire.com/news-releases/faruqi--faruqi-reminds-rocket-pharmaceuticals-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-11-2025---rckt-302525501.html
[3] https://www.marketscreener.com/news/faruqi-faruqi-reminds-rocket-pharmaceuticals-investors-of-the-pending-class-action-lawsuit-with-a-ce7c5ed2d981f121
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet